AZN logo

AZN

AstraZeneca PLC

$204.27
$0.00(0.00%)
67
Overall
70
Value
81
Tech
52
Quality
How is this score calculated?
Market Cap
$628.63B
Volume
2.24M
52W Range
$61.24 - $212.71
Target Price
$205.49

Company Overview

Mkt Cap$628.63BPrice$204.27
Volume2.24MChange+0.00%
P/E Ratio89.4Open$205.45
Revenue$54.1BPrev Close$204.27
Net Income$7.0B52W Range$61.24 - $212.71
Div Yield5.30%Target$205.49
Overall67Value70
Quality52Technical81

No chart data available

About AstraZeneca PLC

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company offers Imjudo, Datroway, Iressa, Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Crestor, Seloken, Lokelma, Roxadustat, Andexxa, Wainua, Symbicort, Fasenra, Pulmicort, Breztri/Trixeo, Saphnelo, Tezspire, Airsupra, Ultomiris, Soliris, Strensiq, Koselugo, Kanuma, Atacand, Plendil, Modip, Splendil, Munobal, Flodil, Komboglyze, Qtern, Byetta, XIGDUO, Accolate, Accoleit, Vanticon, Beyfortus, Synagis, FluMist, tixagevimab and cilgavimab, and sipavibart. It also provides Bricanyl Respules, Eklira Genuair/Tudorza/Bretaris, Bricanyl Turbuhaler, Rhinocort, Bevespi Aerosphere, Daliresp/Daxas, Oxis Turbuhaler, Breztri Aerosphere, Duaklir Genuair, Kavigale, Evusheld, Fluenz/FluMist, and Voydeya. The company offers its products for ocology, cardiovascular, renal and metabolism, respiratory & immunology, vaccines and immune, and therapies rare diseases. It serves primary and specialty care physicians through distributors and local representative offices in the United Kingdom, the United States, Europe, and Asia. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Sector: Healthcare
Industry: Drug Manufacturers - Major

Latest News

AstraZeneca Wins Strong Shareholder Backing at 2026 AGM

AstraZeneca ( ($GB:AZN) ) has shared an update. AstraZeneca shareholders overwhelmingly approved all resolutions at the 9 April 2026 Annual General...

TipRanks UK Auto-Generated Newsdeskin 5 hours

AstraZeneca Extends Fasenra’s Runway With New Long-Term Safety Study

TipRanks Clinical-Trials-Auto-Generated Newsdesk19 hours ago

ESPERANZA Update: Real-World Data Study Could Broaden AstraZeneca’s T-DXd Cancer Opportunity

TipRanks Clinical-Trials-Auto-Generated Newsdesk19 hours ago

J.P. Morgan Reaffirms Their Buy Rating on AstraZeneca (AZN)

TipRanks Auto-Generated Intelligence Newsdesk2 days ago

AstraZeneca (AZN) Receives a Buy from Goldman Sachs

TipRanks Auto-Generated Intelligence Newsdesk6 days ago
ABCD
1SymbolPriceChangeVol
2AZN$204.270%2.24M
3
4
5
6

Get AstraZeneca PLC Data in Excel

Stream real-time data directly to your spreadsheets

BUY NOW
Stock data provided by MarketXLS.